Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gabapentin for refractory rosacea
ChiCTR2200058642Phase 4Not yet recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of gabapentin in rosacea (3 arms), sponsored by Xiangya Hospital, Central South University. Primary endpoints: Rosacea Clinical Symptom Severity Assessment (Patient Assessment) and Rosacea Clinical Symptom Severity Assessment (Physician Assessment). Planned start May 2022; status: not yet recruiting.
02
Drugs
gabapentin
03
Conditions
rosacea
Beyond the preview
Go deeper on ChiCTR2200058642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058642.